Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | CRHBP | P24387 | 1/20 | 0.58 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA7 | P43166 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16026508 | 0.90 | ALDH1A1 (0.70) | SMN1; SMN2ALDH1A1MAPTLMNAAKR1C3 | |
| SCHEMBL1711059 | 0.86 | MEN1 (0.67) | SMN1; SMN2ALDH1A1MAPTLMNANPC1 | |
| SCHEMBL23008882 | 0.85 | ESR1 (0.66) | SMN1; SMN2ALDH1A1MAPTLMNAAKR1C3 | |
| SCHEMBL3439980 | 0.84 | POLB (0.73) | SMN1; SMN2ALDH1A1MAPTLMNAAKR1C3 | |
| SCHEMBL9152022 | 0.84 | CA12 (0.77) | SMN1; SMN2ALDH1A1LMNANPC1HTT | |
| SCHEMBL26706248 | 0.84 | NPC1 (0.71) | SMN1; SMN2ALDH1A1MAPTLMNANPC1 | |
| SCHEMBL1845373 | 0.83 | ALDH1A1 (0.67) | SMN1; SMN2ALDH1A1MAPTLMNAHTT | |
| SCHEMBL15722399 | 0.81 | ALDH1A1 (0.69) | SMN1; SMN2ALDH1A1MAPTLMNANPC1 | |
| SCHEMBL7956657 | 0.80 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1LMNAAKR1C3CA12 | |
| SCHEMBL12082812 | 0.80 | LMNA (0.69) | SMN1; SMN2ALDH1A1MAPTLMNAAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730672-B2 | PROTEASE INHIBITOR | ZENECA LIMITED (GB) | 2004-05-04 | — | — | US | disclosed |
| US-20020119968-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED | 2002-08-29 | — | — | US | disclosed |
| US-6313127-B1 | FOR THERAPY OF HYPERCHOLESTEROLEMIA OR ATHEROSCLEROSIS | ZENECA LIMITED (GB) | 2001-11-06 | — | — | US | disclosed |
| US-6225309-B1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED (GB) | 2001-05-01 | — | — | US | disclosed |
| US-5965559-A | STRONG INHIBITORY EFFECT AGAINST THE ACTIVATED COAGULATION PROTEASE KNOWN AS FACTOR XA; PREVENTION OF THE CLEAVAGE OF PROTHROMBIN TO THROMBIN; AMINO-SUBSTITUTED PYRIMIDINES AMIDINE GROUP-FREE | ZENECA LIMITED (GB) | 1999-10-12 | — | — | US | disclosed |
| EP-0880501-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICAL AGENTS | ZENECA LIMITED (GB) | 1998-12-02 | — | — | EP | disclosed |
| EP-0783500-B1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LTD (GB) | 1998-07-22 | — | — | EP | disclosed |
| WO-1997028128-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICAL AGENTS | ZENECA LIMITED (GB) | 1997-08-07 | — | — | WO | disclosed |
| EP-0783500-A1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LIMITED (GB) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996010022-A1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LIMITED (GB) | 1996-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119968-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | SERPINC1, F2, SULT1E1 | SMN1; SMN2 2956/4885ALDH1A1 1423/4885MAPT 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.